Open AccessComparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation
Author(s) -
Αlexandros Briasoulis,
Amgad Mentias,
Alexander Mazur,
Paulino Álvarez,
Enrique C. Leira,
Mary Vaughan-Sarrazin
Publication year - 2021
Publication title -
cardiovascular drugs and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 69
eISSN - 1573-7241
pISSN - 0920-3206
DOI - 10.1007/s10557-020-07126-2
Subject(s) - medicine , apixaban , dabigatran , rivaroxaban , warfarin , atrial fibrillation , stroke (engine) , hazard ratio , cohort , cardiology , confidence interval , mechanical engineering , engineering
Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF).